Duearity AB (publ) (DEAR.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.58 Million SEK | 68.75% |
| 2022 | 12.79 Million SEK | -16.72% |
| 2021 | 15.35 Million SEK | 4085.15% |
| 2020 | 367 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.78 Million SEK | -31.1% |
| 2024 Q1 | 6.94 Million SEK | -43.11% |
| 2023 FY | 21.58 Million SEK | 68.75% |
| 2023 Q2 | 4.53 Million SEK | 112.17% |
| 2023 Q1 | 2.13 Million SEK | -9.03% |
| 2023 Q4 | 12.21 Million SEK | 115.0% |
| 2023 Q3 | 5.67 Million SEK | 25.31% |
| 2022 Q4 | 2.34 Million SEK | -24.7% |
| 2022 FY | 12.79 Million SEK | -16.72% |
| 2022 Q1 | 3.48 Million SEK | -24.75% |
| 2022 Q3 | 3.11 Million SEK | -18.82% |
| 2022 Q2 | 3.84 Million SEK | 10.22% |
| 2021 Q3 | 3.92 Million SEK | -6.15% |
| 2021 FY | 15.35 Million SEK | 4085.15% |
| 2021 Q4 | 4.63 Million SEK | 18.09% |
| 2021 Q1 | 1.41 Million SEK | 0.0% |
| 2021 Q2 | 4.17 Million SEK | 194.71% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | 367 Thousand SEK | 0.0% |
| 2020 Q3 | 224 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 73.947% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 96.472% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 96.472% |
| Arcoma AB | 53.25 Million SEK | 59.466% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -334.393% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.242% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 89.743% |
| CellaVision AB (publ) | 295.99 Million SEK | 92.708% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 68.686% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -1548.738% |
| C-Rad AB (publ) | 3.8 Million SEK | -468.026% |
| Dignitana AB (publ) | 74.73 Million SEK | 71.118% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -699.444% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.799% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -18.413% |
| Iconovo AB (publ) | 63.35 Million SEK | 65.93% |
| Integrum AB (publ) | 90.57 Million SEK | 76.168% |
| Luxbright AB (publ) | 23.09 Million SEK | 6.52% |
| Mentice AB (publ) | 237.06 Million SEK | 90.895% |
| OssDsign AB (publ) | 175.6 Million SEK | 87.708% |
| Paxman AB (publ) | 133.8 Million SEK | 83.868% |
| Promimic AB (publ) | 48.55 Million SEK | 55.543% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 86.708% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 69.154% |
| ScandiDos AB (publ) | 61.03 Million SEK | 64.637% |
| Sectra AB (publ) | 39.06 Million SEK | 44.743% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 87.632% |
| Senzime AB (publ) | 141.51 Million SEK | 84.747% |
| SpectraCure AB (publ) | 12.12 Million SEK | -77.977% |
| Stille AB | 87.21 Million SEK | 75.252% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.612% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 95.105% |